On February 13, 2025, Junevity, a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases, announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. Wilson Sonsini Goodrich & Rosati advised Junevity on the transaction.

The Junevity RESET platform is based on exclusively licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco. RESET uses large-scale human data and AI to identify genes—or transcription factors—that can regulate cell damage. Then, it develops siRNA therapeutics against these targets to return cells to health. Junevity will use this seed funding to enhance the RESET platform and develop its first therapeutic candidates in Type 2 diabetes, obesity, and frailty.

The Wilson Sonsini team that advised Junevity on the transaction included James Huie and James Kim.

For more information, please see Junevity’s news release.